{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:55:46Z","timestamp":1792007746242,"version":"4.4.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.clinre.2020.10.012","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T19:48:40Z","timestamp":1607716120000},"page":"101568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"45","author":[{"given":"Maria-Styliani","family":"Kalogirou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Bettina","family":"Haidich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Akriviadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Sinakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2020.10.012_bib0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/liv.13299","article-title":"The epidemiology of non-alcoholic fatty liver disease","volume":"37","author":"Bellentani","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2020.10.012_bib0010","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.10.012_bib0015","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.10.012_bib0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and Nonalcoholic Steatohepatitis in the United States and the rest of the world","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinre.2020.10.012_bib0025","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0030","unstructured":"World Health Organization (WHO). Obesity and overweight. Obtained from the world wide web at: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"10.1016\/j.clinre.2020.10.012_bib0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.10.012_bib0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/157339913804143225","article-title":"Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes","volume":"9","author":"Fu","year":"2013","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.clinre.2020.10.012_bib0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","article-title":"Association of nonalcoholic fatty liver disease with insulin resistance","volume":"107","author":"Marchesini","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.clinre.2020.10.012_bib0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/jhep.2002.30692","article-title":"NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome","volume":"35","author":"Chitturi","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.10.012_bib0055","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.gtc.2016.07.003","article-title":"Nonalcoholic fatty liver disease: pathophysiology and management","volume":"45","author":"Carr","year":"2016","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.clinre.2020.10.012_bib0060","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1042\/CS20170987","article-title":"Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?","volume":"131","author":"Gastaldelli","year":"2017","journal-title":"Clin Sci"},{"key":"10.1016\/j.clinre.2020.10.012_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2020.10.012_bib0070","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.clinre.2020.10.012_bib0075","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/hr.2010.60","article-title":"Fatty liver disease: the hepatic manifestation of metabolic syndrome","volume":"33","author":"Gastaldelli","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.clinre.2020.10.012_bib0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1210\/er.2012-1009","article-title":"Diabetes and nonalcoholic fatty liver disease: a pathogenic duo","volume":"34","author":"Williams","year":"2013","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinre.2020.10.012_bib0085","doi-asserted-by":"crossref","first-page":"e8179","DOI":"10.1097\/MD.0000000000008179","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis","volume":"96","author":"Dai","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinre.2020.10.012_bib0090","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinre.2020.10.012_bib0095","doi-asserted-by":"crossref","first-page":"d3897","DOI":"10.1136\/bmj.d3897","article-title":"How big a problem is non-alcoholic fatty liver disease?","volume":"343","author":"Anstee","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2020.10.012_bib0100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2020.10.012_bib0105","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.clinre.2020.10.012_bib0115","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis [published online ahead of print, 2020 May 12]","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.14401","article-title":"Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease","volume":"47","author":"Sookoian","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2020.10.012_bib0125","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhepr.2019.08.002","article-title":"Non-alcoholic fatty liver disease in lean individuals","volume":"1","author":"Albhaisi","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.clinre.2020.10.012_bib0130","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.30908","article-title":"Lean NAFLD: a distinct entity shaped by differential metabolic adaptation","volume":"71","author":"Chen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.10.012_bib0135","article-title":"Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid [published online ahead of print, 2019 Oct 11]","author":"Eshraghian","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2337\/cd18-0026","article-title":"Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality","volume":"37","author":"Golabi","year":"2019","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.clinre.2020.10.012_bib0145","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.10.012_bib0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"key":"10.1016\/j.clinre.2020.10.012_bib0155","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2020.10.012_bib0160","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2020.10.012_bib0165","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinre.2020.10.012_bib0170","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of Ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinre.2020.10.012_bib0175","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hepr.13236","article-title":"Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial)","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clinre.2020.10.012_bib0180","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4254\/wjh.v10.i11.790","article-title":"Treating nonalcoholic steatohepatitis with antidiabetic drugs: will GLP-1 agonists end the struggle?","volume":"10","author":"Kalogirou","year":"2018","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrd3148","article-title":"Liraglutide","volume":"9","author":"Drucker","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinre.2020.10.012_bib0190","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/dmrr.2561","article-title":"Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes","volume":"30","author":"Shao","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinre.2020.10.012_bib0195","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1590\/S0004-27302013000900005","article-title":"Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease","volume":"57","author":"Fan","year":"2013","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0200","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.endonu.2016.01.006","article-title":"Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: an observational, pilot study","volume":"63","author":"Garc\u00eda D\u00edaz","year":"2016","journal-title":"Endocrinol Nutr"},{"key":"10.1016\/j.clinre.2020.10.012_bib0205","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/hepr.12837","article-title":"Effect of 12-week dulaglutide therapy in Japanese\u2009patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"47","author":"Seko","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clinre.2020.10.012_bib0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diabres.2015.12.003","article-title":"Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide","volume":"113","author":"Savvidou","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinre.2020.10.012_bib0215","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/bcpt.13082","article-title":"Liraglutide decreases hepatic inflammation and injury in advanced lean non-alcoholic steatohepatitis","volume":"123","author":"Ipsen","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0220","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0225","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2020.10.012_bib0230","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.clinre.2020.10.012_bib0235","series-title":"Cochrane handbook for systematic reviews of interventions.Version 5.1.0 [updated March 2011]","year":"2011"},{"key":"10.1016\/j.clinre.2020.10.012_bib0240","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.clinre.2020.10.012_bib0245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/dmrr.2713","article-title":"Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies","volume":"32","author":"Tang","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinre.2020.10.012_bib0250","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2020.10.012_bib0255","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/1753-0407.12555","article-title":"Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease","volume":"9","author":"Feng","year":"2017","journal-title":"J Diabetes"},{"key":"10.1016\/j.clinre.2020.10.012_bib0260","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.clinre.2020.10.012_bib0265","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181304","article-title":"Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease","volume":"38","author":"Tian","year":"2018","journal-title":"Biosci Rep"},{"key":"10.1016\/j.clinre.2020.10.012_bib0270","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, Sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.10.012_bib0275","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/dme.12144","article-title":"Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies","volume":"30","author":"Ferwana","year":"2013","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinre.2020.10.012_bib0280","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.diabres.2017.11.002","article-title":"An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug\u2019s effect on cardiovascular disease and non-alcoholic steatohepatitis","volume":"135","author":"Davidson","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinre.2020.10.012_bib0285","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5414\/CP202670","article-title":"Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis","volume":"55","author":"Li","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinre.2020.10.012_bib0290","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-142-1-200501040-00110","article-title":"Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality","volume":"142","author":"Miller","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinre.2020.10.012_bib0295","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin e and the risk of prostate cancer: the selenium and vitamin e Cancer prevention trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clinre.2020.10.012_bib0300","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study","volume":"47","author":"Ekstedt","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0305","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0310","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.metabol.2008.07.030","article-title":"Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia","volume":"57","author":"Hyogo","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.clinre.2020.10.012_bib0315","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0320","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1872-034X.2010.00644.x","article-title":"Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: an open-label, pilot study","volume":"40","author":"Yoneda","year":"2010","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clinre.2020.10.012_bib0325","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00535-010-0291-8","article-title":"Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease","volume":"46","author":"Park","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0330","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","article-title":"The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial","volume":"57","author":"Takeshita","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinre.2020.10.012_bib0335","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.27647","article-title":"Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)","volume":"61","author":"Loomba","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2020.10.012_bib0340","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/dmrr.2561","article-title":"Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes","volume":"30","author":"Shao","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinre.2020.10.012_bib0345","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1590\/S0004-27302013000900005","article-title":"Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease","volume":"57","author":"Fan","year":"2013","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0350","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005325","article-title":"Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes","volume":"4","author":"Gluud","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinre.2020.10.012_bib0360","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinre.2020.10.012_bib0365","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.clinre.2020.10.012_bib0370","unstructured":"Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. ClinicalTrials.gov Identifier: NCT02970942. Accessed online at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02970942."},{"key":"10.1016\/j.clinre.2020.10.012_bib0375","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.12351","article-title":"Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)","volume":"45","author":"Eguchi","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clinre.2020.10.012_bib0380","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study","volume":"102","author":"Petit","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinre.2020.10.012_bib0385","doi-asserted-by":"crossref","first-page":"7399","DOI":"10.12659\/MSM.911062","article-title":"Efficacy and clinical value of liraglutide for treatment of diabetes mellitus complicated by non-alcoholic fatty liver disease","volume":"24","author":"Zhang","year":"2018","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clinre.2020.10.012_bib0390","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clinre.2016.11.009","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Dong","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinre.2020.10.012_bib0395","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/jgh.13026","article-title":"Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"31","author":"Carbone","year":"2016","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740120303090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740120303090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:20:23Z","timestamp":1755084023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740120303090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2210740120303090"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2020.10.012","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2020.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101568"}}